Intestinal microbiota changes after solid organ transplantation: a systematic review by Carra Forte, Cristina et al.
Review Article
http://seer.ufrgs.br/hcpa ISSN 2357-9730 87
Clin Biomed Res. 2018;38(1) :87-92
http://dx.doi.org/10.4322/2357-9730.78354
IntestInal mIcrobIota changes after solId organ transplantatIon:  
a systematIc revIew
Cristina Carra Forte1, Elis Forcellini Pedrollo1,  
Gabriela Corrêa Souza2,3, Cristiane Bauermann Leitão1,4
1 Programa de Pós-Graduação em 
Ciências Médicas: Endocrinologia, 
Universidade Federal do Rio Grande do 
Sul (UFRGS). Porto Alegre, RS, Brasil.
2 Departamento de Nutrição, Faculdade de 
Medicina, Universidade Federal do Rio 
Grande do Sul (UFRGS). Porto Alegre, 
RS, Brasil.
3 Divisão de Nutrição, Hospital de Clínicas 
de Porto Alegre (HCPA). Porto Alegre, 
RS, Brasil.
4 Divisão de Endocrinologia, Hospital de 
Clínicas de Porto Alegre (HCPA). Porto 
Alegre, RS, Brasil.
 Corresponding author: 
Cristina Carra Forte 
criscarraforte@yahoo.com.br 
Programa Pós-graduação em Ciências 
Médicas: Endocrinologia, Universidade 
Federal do Rio Grande do Sul (UFRGS) 
Rua Ramiro Barcelos, 2400. 
90040-341, Porto Alegre, RS, Brasil.
ABSTRACT
Introduction: The intestinal microbiota may undergo changes after solid organ 
transplantation. The purpose of this systematic review was to characterize the intestinal 
microbiota of patients undergoing solid organ transplantation.
Methods: MEDLINE, EMBASE and Cochrane Library databases were searched from 
inception to July 21, 2017. Studies of patients undergoing solid organ transplantation 
that evaluated changes in intestinal microbiota composition and one of the following 
outcomes were included: post-transplant weight, new-onset diabetes after transplantation, 
delayed graft function, acute rejection, graft and patient survival, and post-transplant 
infections.
Results: Out of 765 studies found in this search, two studies (86 patients) fulfilled 
inclusion criteria. Both studies assessed kidney transplantation recipients, and a 
reduction in bacterial species diversity after transplantation was observed. Changes 
in intestinal microbiota were associated with acute rejection in both studies. One study 
reported diarrhea and urinary infections, while the other one reported urinary and 
respiratory infections. None of them reported other outcomes of interest.
Conclusion: Changes in intestinal microbiota were observed after kidney transplantation, 
and they were associated with higher incidence of acute rejection and infections in 
transplant recipients. However, data are still scarce and more studies are needed to 
evaluate if microbiota changes have an impact on post-transplant outcomes.
Keywords: Transplantation; intestinal microbiota; outcomes
The intestinal microbiota is composed mainly by bacteria, which find a 
favorable environment for proliferation. Deregulation of intestinal mucosal 
homeostasis leads to the development of diseases and detrimental conditions 
to the host1,2. These intestinal microbial communities perform some beneficial 
functions to their hosts, which are divided into three levels: (1) biological, as 
barriers against pathogenic microorganisms; (2) immunomodulatory, as a 
stimulus to the local and systemic immune system; and, finally, (3) nutritional 
and metabolic, involving the fermentation of food products and production 
of nutrients3-6.
Changes in the intestinal microbiota have been reported in individuals with 
obesity and/or metabolic syndrome (MS)7-9. Obesity development is associated 
with specific phylum of bacteria inhabiting the human gut8,10,11. Thus, obese 
individuals may have a higher proportion of Firmicutes and a lower proportion 
of Bacteroides compared with individuals with healthy weight8. Furthermore, 
some authors have suggested that treatments with emphasis on balancing 
gut microbiota may be an alternative for obesity treatment7-9. Regarding MS, 
the intestinal microbiota has an important role in metabolic balance, affecting 
the absorption of glucose and lipids and intestinal motility7.
Conversely, the intestinal microbiota may influence solid organ transplant 
outcomes. The gut microbiota of organ transplant recipients is expected to 
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undergo changes in its composition, as the majority 
of patients use antibiotics as prophylaxis or treatment 
of infections during initial hospitalization12-16. Since 
changes in the gut microbiota are associated with 
metabolic disarrangements in both the obese and 
the MS population, as described above7-9, similar 
effects might be observed in organ transplant 
recipients. Advances in immunosuppressive 
therapy have improved post-transplant outcomes 
in recent decades, increasing both graft and patient 
survival17-19. However, organ transplant recipients 
continue to show higher mortality than the general 
population, and this fact is directly related to the 
increased incidence of cardiovascular disease in the 
post-transplant period17,20-26. Several factors have 
been associated with increased cardiovascular risk 
after transplantation, especially the development 
of MS27-31. It is known that weight gain is significant 
in transplanted patients, affecting 30-50% of these 
individuals32-34. In addition, both obesity and MS are 
associated with worse outcomes after transplant34-36.
Few studies have evaluated the composition of the 
intestinal microbiota in organ transplant recipients. 
Thus, the objective of this systematic review was 
to characterize the intestinal microbiota in patients 
undergoing solid organ transplantation and its possible 
associations with post-transplant outcomes.
METHODS
Data Sources and Search
All studies were found using Medical Subject 
Headings (MeSH) and entry terms (Supplementary 
material) while searching MEDLINE (via PubMed), 
EMBASE and Cochrane Library databases, as well as 
gray literature (conference abstracts), from inception 
to July 21, 2017. All relevant articles were considered 
for review regardless of language.
Study Selection
Studies assessing changes in the gut microbiota 
of transplanted patients (kidney, liver, lung, pancreas 
or heart transplantation) were included. Bacterial 
species diversity was defined according to the Shannon 
index, which analyzes the diversity of categorical data 
considering heterogeneity, variety, complexity and 
abundance of bacterial species in the microbiota37.
Studies with replicated data or pediatric patients 
were excluded, as well as studies that assessed 
database populations. Two independent investigators 
performed study selection, initially by titles and 
abstracts, and subsequently by full-text assessment. 
Disagreements were resolved by consensus or a 
third investigator.
Data Extraction and Quality Assessment
Data extraction was performed by two investigators 
according to the following data: author’s name, year 
of publication, number of patients included, length of 
follow-up, demographic characteristics, number of 
fecal samples, microbiota features and the following 
post-transplant outcomes: post-transplant weight gain, 
new-onset diabetes after transplantation (NODAT), 
delayed graft function (DGF), acute rejection, graft 
and patient survival, and post-transplant infections 
(urinary tract, respiratory and intestinal infections). Both 
reviewers were not blinded to authors, institutions or 
article journals. The quality of studies was assessed 
using the Newcastle Quality Assessment Scale38. 
An overall score of 5 or less was considered low 
quality; 6 to 7 was considered moderate quality; and 
8 to 9 was considered high quality. This systematic 
review is described according to Meta-analysis of 
Observational Studies in Epidemiology (MOOSE) 
guidelines39.
RESULTS
Database search identified 765 studies. Of these, 
48 studies were duplicated and 680 studies were 
excluded after an analysis of titles and abstracts. 
The remaining 37 studies were selected for full-text 
assessment, and only two of them fulfilled eligibility 
criteria (Figure 1). Both studies have evaluated the 
gut microbiota and kidney transplant. Table 1 shows 
demographic characteristics of the patients included 
in these studies and Table 2 shows the quality of the 
studies. Main results are described below.
Lee et al.40 have assessed 85 fecal samples 
of 26 kidney transplant recipients. Samples were 
collected during the first 3 months after transplantation 
and accounted at least two per patient. The fecal 
microbial composition was identified by polymerase 
chain reaction (PCR). Reduced bacterial species 
diversity, according to the Shannon index, and 
increased amounts of Proteobacteria were found 
in post-transplant fecal samples compared with 
pre-transplant samples (p = 0.04). Three patients 
with acute rejection showed increased number of 
bacteria from the order Lactobacillales (p = 0. 04) 
and a significant decrease in phylum Bacteroidetes 
(p = 0.03) compared with patients without acute rejection. 
Six patients developed diarrhea in the post-transplant 
period. These patients had decreased amounts of 
Bacteroidales, Bacteroidetes, Ruminococcus and 
Coprococcus compared with those without diarrhea 
(p = 0.007). Finally, patients with urinary tract infection 
(n = 3) showed increased frequency of the genus 
Enterococcus (p = 0.005).
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Figure 1: Identification and selection of articles included in the systematic review.
Table 1: Characteristics of patients from the included studies.
General characteristics StudyLee et al.40 Fricke et al.41
Transplant recipients, n (%)
Men, n (%)
Women, n (%)
26 (100)
13 (50)
13 (50)
60 (100)
38 (63)
22 (37)
Age (years) 56 (46-63) 58 (30-79)
Ethnicity
White, n (%)
Hispanic, n (%)
African American, n (%)
16 (61)
6 (23)
4 (15)
36 (60)
0
24 (40)
Type of transplantation
Living donor, N (%)
Deceased donor, N (%)
14 (54)
12 (46)
N/A
N/A
Organ type
Kidney, N (%)
Simultaneous pancreas and kidney, N (%)
24 (92)
2 (8)
N/A
N/A
Immunosuppression with tacrolimus 26 (100) N/A
Perioperative antibiotics
Cefazolin, n (%)
Vancomycin, n (%)
Ampicilin and Sulbactan, n (%)
21 (81)
3 (11)
2 (8)
N/A
N/A
N/A
N/A: Not available.
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Fricke et al.41 have evaluated 60 patients during the 
first 6 months after kidney transplant and the composition 
of fecal microbiota was evaluated by rectal swab. 
Bacterial species diversity, according to the Shannon 
index, decreased significantly in the first month after 
kidney transplant (p = 0.01), and this change was 
maintained until the assessment of the last sample 
at 6 months. Fermicutes phylum accounted for most 
bacteria observed in the microbiota of post-transplant 
patients. Individuals with acute rejection (n = 4) had a 
significant decrease in four bacterial groups, including 
Anaerotruncus, Coprobacillus, Coprococcus and an 
unknown member of the Peptostreptococcaceae 
(p < 0.005), compared with the 14 patients without 
acute rejection. Four patients had an episode of 
respiratory or urinary tract infection and a decrease 
in the amount of Fermicutes phylum, mainly from 
the genus Anaerotruncus (p < 0.001).
DISCUSSION
This systematic review has revealed that the 
diversity of bacterial species decreases in the 
intestinal microbiota of kidney transplant recipients. 
These alterations in the number of bacteria from 
were associated with acute rejection, diarrhea and 
respiratory and urinary infections.
The human microbiota tends to change rapidly 
during childhood, when food is introduced, and 
more slowly in adult age3. The components of the 
human intestinal microbiota are constantly being 
modified by modern lifestyle. It is well known that 
factors such as host diet, age range, hygiene and 
use of antibiotics play a relevant role in shaping the 
intestinal microbiota5,42,43.
Some key contributing factors are associated with 
intestinal microbiota changing patterns44, and the 
use of antibiotics and immunosuppressive therapy 
are among the most relevant. These interventions 
are associated with decreased intestinal bacteria 
diversity and dysregulation of the immune system, 
and patients undergoing solid organ transplantation 
commonly use both. Antibiotic effects depend on 
composition, dosage, spectrum, route of administration 
and duration of treatment45,46. These medications 
are not always harmless to the transplant patient 
and, in most cases, their frequent use is associated 
with intestinal dysbiosis and production of resistant 
pathogens12.
A retrospective cohort study has reported a 50% 
incidence of infectious episodes in kidney transplant 
recipients during the first months after transplantation 
and concluded that the most frequent infection 
involved the urinary tract, followed by cytomegalovirus, 
surgical incision and lung infections47. Lee et al.48 have 
demonstrated that the most commonly used antibiotics 
for urinary infections are cefazolin and vancomycin. 
Kidney transplant recipients with infections tend to 
be older, to use more potent immunosuppression, to 
have received the graft from a deceased donor and 
to have had a longer time on dialysis47. In addition, 
female gender, prolonged use of urinary catheter, 
retransplantation, cold ischemia time and DGF 
may be risk factors for urinary tract infections47,48. 
Infections remain a recurring problem in transplanted 
patients, resulting in deaths with functioning graft and 
triggering complications that affect the quality of life 
of patients49. Based on this information, the use of 
antibiotics is commonly required post-transplantation, 
and this may be the most important factor leading to 
microbiota changes in these patients.
The intestinal microbiota represents a stimulus for 
the development of the immune system, especially 
the establishment of lymphoid tissues, activation 
of neutrophils, induction of IgA and regulation of 
homeostasis of intestinal T cells (regulatory T cell 
and T helper), which may interfere in the human 
susceptibility to infections and immune-mediated 
diseases50,51. When altered, the microbiota shows 
a reduction in the number of bacteria that favor 
regulatory cells or an increase in the number of cells 
that help the induction of immune systems in response 
to pathogens, leading to infections and diseases in 
individuals52. This deviation from a more tolerant 
immune system to the activation of effector cells may 
be the link between post-transplant microbiota changes 
and acute rejection observed in one of the studies40,51. 
However, further studies should be performed to 
evaluate the association of the intestinal microbiota 
with the mechanisms of infection development and 
acute rejection in transplant patients.
This systematic review has some limitations, 
including the scant number of studies assessing 
intestinal microbiota in patients after solid organ 
transplantation and their small sample size and 
clinical heterogeneity. Also, another clear limitation 
was the difference in the methods used in the studies 
for collecting microbiota samples.
Table 2: Quality scoring based on the Newcastle-Ottawa 
Quality Assessment Scale.
Study (ref) Selection Comparability Outcome
Lee et al.40 *** - ****
Fricke et al.41 **** - ****
Ref = reference number. Note: study groups were controlled for 
age, gender and donor type for assessment of comparability. 
* = Scores.
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CONCLUSION
Changes in the intestinal microbiota were 
observed after kidney transplantation, and they 
were associated with higher incidence of acute 
rejection and infections in recipients. However, 
data are still scarce and more studies are needed 
to evaluate if microbiota changes have an impact 
on other metabolic and graft-related post-transplant 
outcomes.
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